{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:45:05Z","timestamp":1788209105288,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,11,23]],"date-time":"2008-11-23T00:00:00Z","timestamp":1227398400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s11906-008-0092-0","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T12:38:12Z","timestamp":1227357492000},"page":"496-503","source":"Crossref","is-referenced-by-count":29,"title":["Resistant hypertension and hyperaldosteronism"],"prefix":"10.1007","volume":"10","author":[{"given":"Carolina C.","family":"Gonzaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Calhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,11,23]]},"reference":[{"key":"92_CR1","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","volume":"51","author":"D.A. Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, et al.: AHA Scientific Statement. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403\u20131419.","journal-title":"Hypertension"},{"key":"92_CR2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.290.2.199","volume":"290","author":"I. Hajjar","year":"2003","unstructured":"Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988\u20132000. JAMA 2003, 290:199\u2013206.","journal-title":"JAMA"},{"key":"92_CR3","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/HYPERTENSIONAHA.107.107086","volume":"51","author":"J. Ma","year":"2008","unstructured":"Ma J, Stafford RS: Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension 2008, 51:1275\u20131281.","journal-title":"Hypertension"},{"key":"92_CR4","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT OfficersCoordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981\u20132997.","journal-title":"JAMA"},{"key":"92_CR5","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000240931.90917.0c","volume":"48","author":"J. Ma","year":"2006","unstructured":"Ma J, Lee K, Sttaford RS: Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension 2006, 48:846\u2013852.","journal-title":"Hypertension"},{"key":"92_CR6","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"K.K. Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al.: Characterization of resistant hypertension. Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008, 168:1159\u20131164.","journal-title":"Arch Intern Med"},{"key":"92_CR7","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.283.14.1829","volume":"283","author":"F.J. Nieto","year":"2000","unstructured":"Nieto FJ, Young TB, Lind BK, et al.: Association of sleepdisordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 2000, 283:1829\u20131836.","journal-title":"JAMA"},{"key":"92_CR8","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200005113421901","volume":"342","author":"P.E. Peppard","year":"2000","unstructured":"Peppard PE, Young T, Palta M, et al.: Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000, 342:1378\u20131384.","journal-title":"N Engl J Med"},{"key":"92_CR9","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1097\/00004872-200112000-00022","volume":"19","author":"A.G. Logan","year":"2001","unstructured":"Logan AG, Perlikowski SM, Mente A, et al.: High prevalence of unrecognized sleep apnea in drug-resistant hypertension. J Hypertens 2001, 19:2271\u20132277.","journal-title":"J Hypertens"},{"key":"92_CR10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/01.CIR.0000042706.47107.7A","volume":"107","author":"H.F. Becker","year":"2003","unstructured":"Becker HF, Jerrentrup A, Ploch T, et al.: Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003, 107:68\u201373.","journal-title":"Circulation"},{"key":"92_CR11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/thx.2003.015875","volume":"59","author":"G.V. Robinson","year":"2004","unstructured":"Robinson GV, Stradling JR, Davies RJO: Obstructive sleep apnea\/hypopnoea syndrome and hypertension. Thorax 2004, 59:1089\u20131094.","journal-title":"Thorax"},{"key":"92_CR12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1681\/ASN.2007111204","volume":"19","author":"S.C. Textor","year":"2008","unstructured":"Textor SC: Atherosclerotic renal artery stenosis. Overtreated but underrated? J Am Soc Nephrol 2008, 19:656\u2013659.","journal-title":"J Am Soc Nephrol"},{"key":"92_CR13","first-page":"3","volume":"45","author":"J.W. Conn","year":"1955","unstructured":"Conn JW: Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955, 45:3\u201317.","journal-title":"J Lab Clin Med"},{"key":"92_CR14","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"G.P. Rossi","year":"2006","unstructured":"Rossi GP, Bernini G, Caliumi C, et al.: A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293\u20132300.","journal-title":"J Am Coll Cardiol"},{"key":"92_CR15","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1440-1681.1993.tb01687.x","volume":"20","author":"R.D. Gordon","year":"1993","unstructured":"Gordon RD, Ziesak MD, Tunny TJ, et al.: Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993, 20:296\u2013298.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"92_CR16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1440-1681.1994.tb02519.x","volume":"21","author":"R.D. Gordon","year":"1994","unstructured":"Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315\u2013318.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"92_CR17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","volume":"42","author":"L. Mosso","year":"2003","unstructured":"Mosso L, Carvajal C, Gonz\u00e1lez A, et al.: Primary aldosteronism and hypertensive disease. Hypertension 2003, 42:161\u2013165.","journal-title":"Hypertension"},{"key":"92_CR18","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"D.A. Calhoun","year":"2002","unstructured":"Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892\u2013896.","journal-title":"Hypertension"},{"key":"92_CR19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/HYPERTENSIONAHA.106.086116","volume":"50","author":"D.A. Calhoun","year":"2007","unstructured":"Calhoun DA: Is there an unrecognized epidemic of primary aldosteronism? Pro. Hypertension 2007, 50:447\u2013453.","journal-title":"Hypertension"},{"key":"92_CR20","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0272-6386(01)80117-7","volume":"37","author":"B.J. Gallay","year":"2001","unstructured":"Gallay BJ, Ahmad S, Xu L, et al.: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:669\u2013705.","journal-title":"Am J Kidney Dis"},{"key":"92_CR21","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1097\/00004872-200411000-00026","volume":"22","author":"I.K. Eide","year":"2004","unstructured":"Eide IK, Torjesen PA, Drolsum A, et al.: Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004, 22:2217\u20132226.","journal-title":"J Hypertens"},{"key":"92_CR22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.jhh.1001554","volume":"17","author":"B. Strauch","year":"2003","unstructured":"Strauch B, Zelinka T, Hampf M, et al.: Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003, 17:349\u2013352.","journal-title":"J Hum Hypertens"},{"key":"92_CR23","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","volume":"371","author":"S. Douma","year":"2008","unstructured":"Douma S, Petidis K, Doumas M, et al.: Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008, 371:1921\u20131926.","journal-title":"Lancet"},{"key":"92_CR24","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R. Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802\u2013H1810.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"92_CR25","first-page":"893","volume":"120","author":"C.G. Brilla","year":"1992","unstructured":"Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893\u2013901.","journal-title":"J Lab Clin Med"},{"key":"92_CR26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/HYPERTENSIONAHA.107.095489","volume":"51","author":"N.J. Brown","year":"2008","unstructured":"Brown NJ: Aldosterone and vascular inflammation. Hypertension 2008, 51:161\u2013167.","journal-title":"Hypertension"},{"key":"92_CR27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"G.P. Rossi","year":"1996","unstructured":"Rossi GP, Sacchetto A, Visentin P, et al.: Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996, 27:1039\u20131045.","journal-title":"Hypertension"},{"key":"92_CR28","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1038\/sj.ki.5000378","volume":"69","author":"C.S. Fox","year":"2006","unstructured":"Fox CS, Larson MG, Hwang S-J, et al.: Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006, 69:2064\u20132069.","journal-title":"Kidney Int"},{"key":"92_CR29","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1161\/01.CIR.0000129307.26791.8E","volume":"109","author":"M.K. Nishizaka","year":"2004","unstructured":"Nishizaka MK, Zaman MA, Green SA, et al.: Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857\u20132861.","journal-title":"Circulation"},{"key":"92_CR30","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/HJH.0b013e3281268532","volume":"25","author":"R. Holaj","year":"2007","unstructured":"Holaj R, Zelinka T, Wichterle D, et al.: Increased intimamedia thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007, 25:1451\u20131457.","journal-title":"J Hypertens"},{"key":"92_CR31","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P. Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, et al.: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243\u20131248.","journal-title":"J Am Coll Cardiol"},{"key":"92_CR32","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/HJH.0b013e3282a9be30","volume":"25","author":"E. Pimenta","year":"2007","unstructured":"Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al.: Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens 2007, 25:2131\u20132137.","journal-title":"J Hypertens"},{"key":"92_CR33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1161\/HYPERTENSIONAHA.107.100701","volume":"51","author":"E. Pimenta","year":"2008","unstructured":"Pimenta E, Gaddam KK, Pratt-Ubunama MN, et al.: Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension 2008, 51:339\u2013344.","journal-title":"Hypertension"},{"key":"92_CR34","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/bmj.38814.566019.2F","volume":"332","author":"M. Tonelli","year":"2006","unstructured":"Tonelli M, Jose P, Curhan G, et al.: Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomized trial. BMJ 2006, 332:1426\u20131431.","journal-title":"BMJ"},{"key":"92_CR35","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"M.K. Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA: Efficacy of lowdose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925\u2013930.","journal-title":"Am J Hypertens"},{"key":"92_CR36","first-page":"564","volume-title":"Hypertension Primer: The Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management","author":"D.A. Calhoun","year":"2008","unstructured":"Calhoun DA: Management of hyperaldosteronism and hypercortisolism. In Hypertension Primer: The Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management. Edited by Izzo JL, Sica D, Black HR. Philadelphia: Lippincott Williams & Wilkins; 2008:564\u2013567."},{"key":"92_CR37","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.amjhyper.2007.08.009","volume":"20","author":"F. Pizzolo","year":"2007","unstructured":"Pizzolo F, Pavan C, Corrocher R, et al.: Laboratory diagnosis of primary aldosteronism, and drospirenone-ethinylestradiol therapy. Am J Hypertens 2007, 20:1334\u20131337.","journal-title":"Am J Hypertens"},{"key":"92_CR38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ncpneph0151","volume":"2","author":"C. Mattsson","year":"2006","unstructured":"Mattsson C, Young WF Jr: Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2006, 2:198\u2013208.","journal-title":"Nat Clin Pract Nephrol"},{"key":"92_CR39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0889-8529(18)30425-0","volume":"17","author":"W.F. Young Jr","year":"1988","unstructured":"Young WF Jr, Klee GC: Primary aldosteronism: diagnostic evaluation. Endocrinol Metab Clin North Am 1988, 17:367\u2013395.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"92_CR40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.107.091827","volume":"50","author":"G.P. Rossi","year":"2007","unstructured":"Rossi GP, Belfiore A, Bernini G, et al.: Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007, 50:424\u2013431.","journal-title":"Hypertension"},{"key":"92_CR41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archsurg.141.5.497","volume":"141","author":"F.E. Nwariaku","year":"2006","unstructured":"Nwariaku FE, Miller BS, Auchus R, et al.: Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006, 141:497\u2013503.","journal-title":"Arch Surg"},{"key":"92_CR42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7326\/0003-4819-135-4-200108210-00010","volume":"135","author":"A.M. Sawka","year":"2001","unstructured":"Sawka AM, Young WF, Thompson GB, et al.: Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001, 135:258\u2013261.","journal-title":"Ann Intern Med"},{"key":"92_CR43","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1161\/HYPERTENSIONAHA.108.111369","volume":"51","author":"G.P. Rossi","year":"2008","unstructured":"Rossi GP, Bolognesi M, Rizzoni D, et al.: Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008, 51:1366\u20131371.","journal-title":"Hypertension"},{"key":"92_CR44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C. Catena","year":"2007","unstructured":"Catena C, Colussi G, Lapenna R, et al.: Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007, 50:911\u2013918.","journal-title":"Hypertension"},{"key":"92_CR45","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1161\/01.HYP.0000016176.16042.2F","volume":"39","author":"S.J. Taler","year":"2002","unstructured":"Taler SJ, Textor SC, Augustine JE: Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002, 39:982\u2013988.","journal-title":"Hypertension"},{"key":"92_CR46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/01.HYP.0000203309.07140.d3","volume":"47","author":"M.E. Ernst","year":"2006","unstructured":"Ernst ME, Carter BL, Goerdt CJ, et al.: Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006, 47:352\u2013358.","journal-title":"Hypertension"},{"key":"92_CR47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0895-7061(01)02342-1","volume":"15","author":"J. Ouzan","year":"2002","unstructured":"Ouzan J, Perault C, Lincoff AM, et al.: The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002, 15:333\u2013339.","journal-title":"Am J Hypertens"},{"key":"92_CR48","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","volume":"25","author":"D.A. Lane","year":"2007","unstructured":"Lane DA, Shah S, Beevers DG: Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 2007, 25:891\u2013894.","journal-title":"J Hypertens"},{"key":"92_CR49","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N. Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, et al.: Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839\u2013845.","journal-title":"Hypertension"},{"key":"92_CR50","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"J.M. Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148\u20131155.","journal-title":"J Am Coll Cardiol"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0092-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-008-0092-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-008-0092-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:22Z","timestamp":1559434462000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-008-0092-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,23]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["92"],"URL":"https:\/\/doi.org\/10.1007\/s11906-008-0092-0","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,23]]}}}